LRRC57 Inhibitors
LRRC57 inhibitors belong to a class of chemical compounds that specifically target and modulate the activity of leucine-rich repeat-containing protein 57 (LRRC57). LRRC57 is a protein characterized by the presence of leucine-rich repeats, structural motifs commonly involved in protein-protein interactions. These inhibitors are designed to selectively bind to LRRC57, thereby altering its function and potentially disrupting associated cellular processes. The leucine-rich repeats in LRRC57 suggest its involvement in mediating interactions with other proteins, and the inhibitors are strategically crafted to interfere with these interactions.
The development of LRRC57 inhibitors is rooted in the understanding that modulating the activity of specific proteins can have profound effects on cellular functions. The design and synthesis of LRRC57 inhibitors involve a detailed understanding of the protein's structure and the identification of key binding sites. These inhibitors hold promise as valuable tools for investigating the molecular mechanisms associated with LRRC57 and its involvement in cellular processes. As research in this field progresses, the intricate details of LRRC57 inhibitors' interactions with the protein may provide insights into novel strategies for manipulating cellular functions for experimental purposes.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases, which can indirectly affect LRRC57 by inhibiting kinases that are potentially involved in the post-translational modification of LRRC57, influencing its activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor, which can indirectly inhibit LRRC57 by blocking the PI3K/Akt pathway that may play a role in the cellular processes governing the localization and function of LRRC57. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor that can indirectly inhibit LRRC57 by affecting the mTOR signaling pathway, potentially influencing the cellular growth and translation processes related to the function of LRRC57. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor which may indirectly inhibit LRRC57 by disrupting the MAPK signaling pathways that could regulate the activity or stability of LRRC57. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 inhibits MEK, which then inhibits ERK pathway activation. This can indirectly affect LRRC57 by altering the signaling pathways that could control its activation or function. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a selective inhibitor of MEK1 and MEK2, which may indirectly inhibit LRRC57 by modulating the MAPK/ERK pathway potentially involved in the regulation of LRRC57 function. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a PI3K inhibitor that can indirectly inhibit LRRC57 by blocking the PI3K/Akt pathway, which may be involved in the regulation of LRRC57's cellular location or activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor potentially affecting LRRC57 by altering JNK signaling pathways that could be involved in the regulation of LRRC57's activity. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor that can indirectly inhibit LRRC57 by preventing the degradation of regulatory proteins that control LRRC57's activity or stability. | ||||||
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $63.00 $92.00 $250.00 $485.00 $1035.00 $2141.00 | 69 | |
Cyclosporin A is an immunosuppressant that can indirectly inhibit LRRC57 by inhibiting calcineurin, thereby potentially affecting the NFAT pathway which might regulate the activity of LRRC57. | ||||||